Cerus (CERS) Projected to Post Quarterly Earnings on Thursday

Cerus (NASDAQ:CERS) is expected to issue its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Cerus Stock Performance

NASDAQ CERS opened at $2.24 on Tuesday. The stock has a market capitalization of $430.28 million, a price-to-earnings ratio of -28.00 and a beta of 1.52. Cerus has a twelve month low of $1.12 and a twelve month high of $2.95. The company has a current ratio of 1.89, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78. The stock has a 50-day moving average of $2.23 and a 200 day moving average of $1.74.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CERS shares. TD Cowen reaffirmed a “buy” rating on shares of Cerus in a research note on Monday, January 12th. Wall Street Zen raised shares of Cerus from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Cerus currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Institutional Trading of Cerus

A number of hedge funds have recently bought and sold shares of the business. Cibc World Markets Corp purchased a new position in Cerus in the 4th quarter worth approximately $25,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Cerus in the third quarter valued at approximately $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cerus in the first quarter valued at approximately $32,000. Aquatic Capital Management LLC purchased a new position in Cerus during the third quarter worth approximately $35,000. Finally, MML Investors Services LLC purchased a new position in Cerus during the fourth quarter worth approximately $37,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.